Trans-Trasman travel bubble to commence from April 19. Source: 1News
Trans-Trasman travel bubble to commence from April 19. Source: 1News
Canon has confirmed a rumor that it's developing the EOS R3, a "high-performance, high-speed" full-frame mirrorless camera designed for news and sports, along with three new lenses.
Forecasts by Model (Peer-to-Peer (P2P), Point-to-Point Free-Floating, Point-to-Point Station Based), by Business Model (Round Trip, One-Way), by Application (Business, Private), by Region Plus Analysis of Leading Companies Developing Technologies for Ride Sharing, Shared Mobility & On-Demand Mobility.New York, April 14, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Car Sharing Market Report 2019-2029" - https://www.reportlinker.com/p06058477/?utm_source=GNW • Do you need definitive Car Sharing market data? • Succinct Car Sharing market analysis? • Technological insight? • Clear competitor analysis? • Actionable business recommendations? The Car Sharing market from 2019-2029 will drive a major transformative effect in the way people use vehicles. The analyst assesses that the Car Sharing market will reach $2.4bn in 2019. There will be exponential growth in the sales and utilisation of Car Sharing and its technology. During this period, the Peer-to-peer model will be one of the fastest growing segments of the Car Sharing market. This brand-new in-depth Car Sharing Market Report 2019-2029 describes trends in the market both quantitatively and qualitatively. In recent years, this global Car Sharing market has undergone increasing investment, as the importance of mobility is surging in both developed and developing nations. Report highlights • 123 Tables, Charts, And Graphs • Analysis Of Key Players In The Car Sharing Market • DriveNow GmbH & Co. KG • ORIX Corporation • Lyft, Inc. • Zipcar, Inc • Modo Co-operative • Getaround, Inc • The Hertz Corporation • Cambio CarSharing • car2go NA, LLC • GoGet Carshare • Uber Technologies, Inc. • Cityhop • Global Car Sharing Market Outlook And Analysis From 2019-2029 • Car Sharing Model Forecasts And Analysis From 2019-2029 • Peer-To-Peer (P2P) Car Sharing Forecast 2019-2029 • Point-To-Point Free-Floating Car Sharing Forecast 2019-2029 • Point-To-Point Station Based Car Sharing Forecast 2019-2029 • Car Sharing Application Forecasts And Analysis From 2019-2029 • Business Car Sharing Forecast 2019-2029 • Private Car Sharing Forecast 2019-2029 • Car Sharing Business Model Forecasts And Analysis From 2019-2029 • Round Trip Sharing Forecast 2019-2029 • One Way Car Sharing Forecast 2019-2029 • Regional Car Sharing Market Forecasts From 2019-2029 • North America Car Sharing Forecast 2019-2029 • US Car Sharing Forecast 2019-2029 • Canada Car Sharing Forecast 2019-2029 • Mexico Car Sharing Forecast 2019-2029 • Europe Car Sharing Forecast 2019-2029 • Germany Car Sharing Forecast 2019-2029 • UK Car Sharing Forecast 2019-2029 • France Car Sharing Forecast 2019-2029 • Italy Car Sharing Forecast 2019-2029 • Switzerland Car Sharing Forecast 2019-2029 • Austria Car Sharing Forecast 2019-2029 • Netherlands Car Sharing Forecast 2019-2029 • Sweden Car Sharing Forecast 2019-2029 • Spain Car Sharing Forecast 2019-2029 • Belgium Car Sharing Forecast 2019-2029 • Rest of Europe Car Sharing Forecast 2019-2029 • Asia Car Sharing Forecast 2019-2029 • China Car Sharing Forecast 2019-2029 • Japan Car Sharing Forecast 2019-2029 • India Car Sharing Forecast 2019-2029 • South Korea Car Sharing Forecast 2019-2029 • Rest of Asia Car Sharing Forecast 2019-2029 • Oceania Car Sharing Forecast 2019-2029 • Australia Car Sharing Forecast 2019-2029 • Rest of Oceania Car Sharing Forecast 2019-2029 • Latin America Car Sharing Forecast 2019-2029 • Brazil Car Sharing Forecast 2019-2029 • Rest of Latin America Car Sharing Forecast 2019-2029 • Key questions answered • What does the future hold for the Car Sharing industry? • Where should you target your business strategy? • Which applications should you focus upon? • Which disruptive technologies should you invest in? • Which companies should you form strategic alliances with? • Which company is likely to success and why? • What business models should you adopt? • What industry trends should you be aware of? Target audience • Leading car sharing companies • On-demand mobility specialists • Telematics companies • Autonomous vehicle companies • Automotive OEMs • Automotive engineers • Technologists • R&D staff • Consultants • Market analysts • Executives • Business development managers • Investors • Governments • Agencies • Industry organisationsRead the full report: https://www.reportlinker.com/p06058477/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: email@example.com US: (339)-368-6001 Intl: +1 339-368-6001
Dublin, April 14, 2021 (GLOBE NEWSWIRE) -- The "US Cancer Antibody Market, Drug Price, Sales & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering. Over the past few years, there has been a growing race to develop an enhanced version of the cancer therapeutics market at the global level. To acquire such growing parameters, the US cancer market started intensifying the importance of the cancer antibody market by making itself among the top markets to establish a complete set of research paradigms important for the respective market. The US cancer antibody market has increased the overall market growth rate and size of the oncology sector, as the respective market carries the ability to optimize the high-ending demands of the cancer patient population for having a stable and efficient therapy for different cancers. In addition, the extensive development rate of healthcare in the form of diagnosis and drug research and development is estimated to benefit the cancer-antibody drug market enormously when compared with other country's market. Cancer antibodies have helped the researchers in leaning the entire cancer therapeutics market towards a great transition i.e. from delivering adverse side effects to receiving tons of healthcare benefits such as no adverse side effects or cancer recurrence. Also, the availability of prominent designing and research tools in the US has also helped scientific researchers to design potent cancer-antibody drugs in terms of functionality, quality, and cost. It can be witnessed for the US cancer antibody drug market that the potential impact of the market on the US cancer market is far ahead of the clinical implications observed for a large base of chemotherapeutics agents and many more. The extensive and well-established base for the oncology sector and specifically cancer-antibody drug market has made the US industry share a big percentage to the global development in this respective market, despite of the fact that there are numerous emerging powers in the world. With excessive use of pharmacoeconomics, relaxed formularies as well as e-prescribing market, high number of payers and healthcare policy-makers are also assessing the market towards boosting the research and development platform of the market by adding monotherapy and bispecific therapy to it. To an extensive level, it is witnessed that the rising volume of research activities and quality of data available in the country has driven the adoption rate of novel drug approvals and grants for research and development platform related to the market. In addition, the primary regulatory body in the country has also made greater use of fast-track methods for making the entire market boomed with breakthroughs and achievements. In the US, technology advancement is also considered a democratizing force for boosting the market paradigm for cancer-antibody drug market. Biotech and bio-pharmaceutical companies are also inducing patient-centric approaches for turning the simple cancer antibody market into a market full of off-to-strategies. In addition, the total spending of medicines in cancer-antibody drug market is expected to increase, thus leading to the adoption of novel wave for innovative and promising products. Some of the prominent factors that will be driving the US cancer antibody drug market are: pricing shifts and emergence and growth of biosimilars. In the respective research report, reported sales, growing trends and opportunities, the challenge for the future market has been compared, thus providing a realistic idea for the market. Key Report Highlights: US Cancer Antibodies Market Opportunity: > US$ 70 Billion by 2026US Cancer Antibodies Market Growth: 100% Absolute Growth Till 2026US Cancer Antibodies Market Size Opportunity by Therapeutic ClassInsight On Clinical Trials by Company, Indication, Patient Segment & PhaseInsight on FDA Approved 57 Cancer Antibodies Available in US MarketPrice, Dosage, Patent & Sales Insight on Cancer Antibodies Available In MarketUS Cancer Biosimilar Market Opportunity Insight: > US$ 10 Billion by 2026 Key Topics Covered: 1. US Cancer Antibodies Market Analysis 2. US Cancer Antibodies Market Segmentation by Therapeutic Class 3. US Breast Cancer Antibodies Market 4. US Blood Cancer Antibody Market 5. US Lung Cancer Antibody Market 6. US Colorectal Cancer Antibodies Market Overview 7. US Cancer Biosimilar Market 8. Global Peptide Cancer Therapeutics Clinical Trials Overview 9. US HER2 Inhibiting Antibodies - Availability, Dosage, Patent, Price & Sales Analysis 10. US VEGF/VEGFR Inhibiting Antibodies -Availability, Dosage, Patent, Price & Sales Analysis 11. US Antibody-Drug Conjugates - Availability, Dosage, Patent, Price & Sales Analysis 12. US CD20-Directed Antibody - Availability, Dosage, Patent, Price & Sales Analysis 13. US Bispecific Antibodies - Availability, Dosage, Patent, Price & Sales Analysis 14. CD52 Monoclonal Antibodies - Availability, Dosage, Patent, Price & Sales Analysis 15. CD38 Monoclonal Antibodies - Availability, Dosage, Patent, Price & Sales Analysis 16. Immune Checkpoint Inhibitor - Availability, Dosage, Patent, Price & Sales Analysis 17. EGFR Inhibitors - Availability, Dosage, Patent, Price & Sales Analysis 18. Combinational Antibodies - Availability, Dosage, Price & Sales Analysis 19. Others Cancer Targeting Antibodies of US - Availability, Dosage, Patent, Price & Sales Analysis 20. Competitive Landscape AmgenAryoGen PharmedAstraZeneca plcBIOCADBoehringer IngelheimBristol Mayer SquibbDaiichi Sankyo CompanyGenentechImmunomedicsInnovent BiologicsJassen PharmaceuticalsMacroGenicsmAbxienceMylanOutlook TherapeuticsPfizerPrestige BiopharmaRocheSamsung BioSeagen For more information about this report visit https://www.researchandmarkets.com/r/nx8oik About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager firstname.lastname@example.org For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Actor’s relationship with singer caused a media frenzy in 2016
Turkey's foreign minister said a new period was beginning in Ankara's ties with Egypt with senior officials from the two countries set to hold talks, broadcaster NTV said on Wednesday. Last month Turkey said it had resumed diplomatic contacts with Egypt and wanted further cooperation after years of tension since the Egyptian army toppled a Muslim Brotherhood president close to Ankara.
US envoy John Kerry will visit China this week for climate change talks -- the first official trip under the Biden administration -- in a trip Washington hopes will put aside diplomatic spats and focus on joint environment challenges.
‘Line of Duty and their Easter eggs constantly amaze me,’ wrote one user
Fast growing RegTech company, Napier, which provides next-generation anti-money laundering (AML) solutions, has bolstered its senior management team with the appointments of new Global Human Resources Director, Lila Boyce, and EMEA Head of Sales, Roy Williamson.
Ben Roberts-Smith's barrister has accused the Nine Network of abusing the court process in its "concerted effort" to publish prejudicial material eight weeks out from the decorated soldier's defamation trial.The war hero is suing the publishers of The Age, The Sydney Morning Herald and The Canberra Times over alleged defamatory articles suggesting he committed war crimes in Afghanistan.
Forecasts by Solution (Enterprise Manufacturing System (EMS), Inventory Management System (IMS), Laboratory Information Management System (LIMS), Logistics Management System (LMS), Patient Management System (PMS), Quality Management System (QMS), Tracking and Tracing System (TTS), Cell Orchestration Platform (COP)), Deployment (On-cloud, Premises), End-user (Bio Bank, Hospital, Cell Therapy Lab, Others), by Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa), Plus Analysis of Leading Cell and Gene Supply Chain Services and Solutions Companies.New York, April 14, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Cell and Gene Supply Chain Services and Solutions Market Report 2020-2030" - https://www.reportlinker.com/p06058479/?utm_source=GNW Cell and Gene Supply Chain Services and Solutions–our new study reveals trends, R&D progress, and predicted revenues Where is the Cell and Gene Supply Chain Services and Solutions market heading? If you are involved in this sector you must read this newly updated report. This report shows you the potential revenues streams to 2030, assessing data, trends, opportunities and business prospects there. Discover how to stay ahead Our 330+ page report provides 500+ tables and charts/graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Cell and Gene Supply Chain Services and Solutions Market. See how to exploit the opportunities. Forecasts to 2030 and other analyses reveal the commercial prospects • In addition to revenue forecasting to 2030, our new study provides you with recent results, growth rates, and market shares. • You find original analyses, with business outlooks and developments. • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments. This report includes data analysis and invaluable insight into how COVID-19 will affect your industry. Access this report today. Discover sales predictions for the world market and submarkets By Solution • Enterprise manufacturing system (EMS) • Inventory management system (IMS) • Laboratory information management system (LIMS) • Logistics management system (LMS) • Patient management system (PMS) • Quality management system (QMS) • Tracking and tracing system (TTS) • Cell orchestration platform (COP) By Deployment • On-Cloud • Premises By End-User • Bio Bank • Hospital • Cell Therapy Lab • Others By Region • North America – U.S. – Canada • Europe – Germany – France – UK – Italy – Spain – Rest of Europe • Asia Pacific – China – Japan – India – Rest of Asia Pacific • Latin America – Brazil – Mexico – Rest of Latin America • Middle East & Africa – GCC – South Africa – Rest of Middle East & Africa There will be growth in both established and in developing countries. Our analyses show that the both developed and developing markets, U.S., Germany, UK and India, China in particular, will continue to achieve high revenue growth to 2030. Leading companies and the potential for market growth Overall world revenue for Cell and Gene Supply Chain Services and Solutions Market will surpass $xx million in 2020, our work calculates. We predict strong revenue growth through to 2030. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead. How the Cell and Gene Supply Chain Services and Solutions Market report helps you In summary, our 330+ page report provides you with the following knowledge: • Revenue forecasts to 2030 for Cell and Gene Supply Chain Services and Solutions Market, with forecasts for Technology and Application, each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues • Revenue forecasts to 2030 for 5 regional and 16 key national markets – See forecasts for the Cell and Gene Supply Chain Services and Solutions market in North America, Europe, Asia-Pacific and Rest of the World. • Prospects for established firms and those seeking to enter the market– including company profiles for 10 of the major companies involved in the Cell and Gene Supply Chain Services and Solutions Market. Some of the company’s profiles in this report include BioLifeSolutions Inc., Be The Match BioTherapies, Cryoport Systems, Inc., McKesson Corporation, MasterControl, Inc., Veeva Systems, TrakCel, WellSky, STEMSOFT Software, and Vineti. Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence. Information found nowhere else With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. This study is for everybody needing commercial analyses for the Cell and Gene Supply Chain Services and Solutions Market and leading companies. You will find data, trends and predictions.Read the full report: https://www.reportlinker.com/p06058479/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: email@example.com US: (339)-368-6001 Intl: +1 339-368-6001
Gibraltar, Israel and many Asia Pacific countries are likely to qualify
Dublin, April 14, 2021 (GLOBE NEWSWIRE) -- The "Clinical Genomics Report: The Interplay Between Clinical Research & Clinical Diagnostics" report has been added to ResearchAndMarkets.com's offering. This "Clinical Genomics Report: The Interplay Between Clinical Research and Clinic Diagnostics" provides an in-depth analysis of differences in product characteristics related to data processing, analysis, knowledge extraction and reporting of findings (including the type of content integrated for meaningful extraction), and compliance and security mechanisms. Both clinical end-users and commercial companies who require insight into this expanding industry and its providers and products will benefit from the critical, investigative, and qualitative report. This new, qualitative report provides an in-depth analysis across the complex, multi-step clinical genomics data process (which includes genomic data generation, data flow, and data warehousing), clinical genomics data solution providers, market trends, technologies impacting clinical genomics applications development, clinical genomics adoption challenges, and detailed challenges & needs analysis as identified in discussions with clinical end-users. The report is unique, in that it is not a predictive market research report, but rather builds on data gathered from many end-user interviews combined with an extensive analysis of the clinical genomics sector. Report Contents: Leading medical organizations have established precision medicine programs that support personalized patient treatment. Implementation of clinical genomics applications and enterprise-wide clinical data warehouses are considered the foundation for successful genomic medicine programs. Innovative technological advancements have allowed us to sequence and uncover mutational events at an unprecedented scale while facilitating linking genomic data to high-quality clinical data and diagnosis. Medical organizations understand the benefit of being empowered by data-driven approaches to reduce operational costs and time and to provide researchers and clinicians what is necessary to decipher critical research data and data for clinical decision making. However, technical and scientific limitations still need to be addressed for optimized and universal use of various data sources for both clinical and research purposes. While data production is no longer a challenge, and targeted panels - and to some extent, whole-exome sequencing - are well adopted, the expected dramatic rise in whole-genome sequencing will result in unforeseeable quantities of data at the clinical level that needs to be managed, understood, and communicated. Low-cost sequencing of whole genomes at population scale is already in existence, but not yet widespread in the clinic, as many observed changes at the genome level cannot yet be fully interpreted or explain an existing phenotype. Scalable, fully automated analysis and knowledge extraction solutions incorporating rich annotation information are necessary to overcome these challenges. With massive quantities of NGS data (linked to different clinical and other types of data), artificial intelligence and machine learning are hailed as pivotal solutions to address the data interpretation and knowledge extraction challenges and to advance the clinical application of genomics. Despite increasing efforts and investments in implementing clinical applications and building data solutions, many organizations are still challenged with the multi-faceted complexities in transforming to become data-driven. Implementations are challenged by ineffective data sharing, scalability and automation issues, non-optimized data generation and data flow approaches and non-standardized data from numerous sources. Implementing a complex clinical data warehouse presents many challenges starting with the various data sources it needs to support and the tools required to view the clinical information. Ingestion of data of different types and origins with relevant metadata; data transformation, standardization, and cleansing to support the needs of a diverse set of end-users in both the clinical and research settings; and varied end-users with individual needs and computation capabilities are all important considerations. Clinical interviews detailed challenges associated with creating a workflow that incorporates a clinical data warehouse connecting clinical research with clinical diagnostics and vice versa. This important workflow leads to efficient clinical decision-making and reporting findings between clinical research and the clinic, which can optimize clinical outcomes and patient treatment. Key Topics Covered: 1. THE CLINICAL DIAGNOSTICS & MOLECULAR PROFILING WORKFLOW Clinical Genomics Workflow End Users/PersonasMapping End Users to the Clinical Genomics WorkflowClinical Information Delivery 2. THE PRECISION MEDICINE VALUE CHAIN 3. LEADING MEDICAL ORGANIZATIONS PLATFORM AND INFRASTRUCTURE PREFERENCES IN SUPPORT OF THEIR CLINICAL GENOMICS WORKFLOWS Implementations and Choices of Molecular Profiling and Genetic Testing ProcessesMedical Organizations' Clinical Genetic Testing LabsTesting Lab Selection CriteriaPlatforms and Infrastructures Currently Implemented at Leading Medical OrganizationsAdoption of Commercial and Internally Developed Platforms, Tools, and ServicesMedical Organizations Platform and Infrastructure PreferencesProfiles of Leading Medical OrganizationsCedars-SinaiEmory HealthcareGeisinger Health SystemsIntermountain HealthcareKaiser PermanenteMayo ClinicMD Anderson Cancer CenterMoffitt Cancer CenterMount Sinai Health SystemNationwide Children's HospitalPartners HealthCareSanford HealthSt. Jude Children's HospitalVanderbilt University Medical Center 4. MEDICAL INDUSTRY CHALLENGES Clinical Genomics - Unmet Needs and ChallengesTechnical Challenges Associated with Scaling Clinical Genomics ApplicationsScientific Challenges Associated with the Implementation of Clinical GenomicsNon-Technical / Scientific Challenges Associated with the Implementation of Clinical Genomics Applications 5. GENOMIC DATA GENERATION, DATA FLOW, AND DATA WAREHOUSING Rethinking Optimized Genomic Data Generation and Data FlowStructures of Successful Big Data PlatformsScalable Data Generation and Data Flow Lacking Data StandardsSlow Integration of Clinical Genomics Data with Other Clinical/Patient DataCurrent EMR/EHR Systems Do Not Support Genomics DataVariant Data Warehousing for Data Analysis, Mining, and QueryingEnterprise Data Platform ArchitectureIntegration of Various Types of DataA Data Warehouse That Supports Clinical ResearchData Warehousing and Fast Data Processing Requires a Scalable InfrastructureThe Ideal Variant Data Analysis and Query PlatformData Warehouse versus a Data LakeCloud Is the Preferred Infrastructure 6. CLINICAL GENOMICS DATA SOLUTIONS Genomic Data Infrastructures/Platforms for Data Storage, Processing, and AnalysisScaled Data Storage and Computing SolutionsClinical Genomics Data PlatformsIntegrated Genomic WorkflowData Processing Speed, Scalability, and FlexibilityClinical Data Management & Knowledge ExtractionClinico-Genomic Data Management and IntegrationGenomic/Variant Data Querying and AnalysisVariant Data Interpretation/Decision Making/ReportingTertiary Analysis - Sequence Data Interpretation and Insight GenerationTertiary Analysis - Embedded Interpretation Content for Insight GenerationData Processing, Knowledge Extraction, and Reporting Companies Side-by-Side 7. CLINICAL GENOMICS MARKET TRENDS Factors Impacting Clinical Sequencing AdoptionGenetic Testing and Molecular Profiling TrendsThe Increasing Trend of Clinical Genetic TestingClinical Genomics Applications to Be Established in the Clinic as a RoutineRoutine Genomic Applications Established over the Next Three to Five YearsRequirements to Establish Genomic Applications as a RoutineMergers, Acquisitions, and Partnerships Accelerate Adoption of Clinical GenomicsAgilent Is Building Integrated, Complete Clinical Workflow SolutionsIllumina's M&As Suggest the Goal of a Fully Integrated Sequencing SolutionRoche Is Expanding its Diagnostics BusinessThermo Fisher Scientific Is Strengthening Its Presence in the Clinical SectorQIAGEN Is Pushing the Molecular Diagnostics and Clinical Research MarketsOther Acquisitions and Partnerships 8. TECHNOLOGIES IMPACTING THE IMPLEMENTATION OF CLINICAL GENOMICS & MOLECULAR PROFILING APPLICATIONS 3rd and 4th Generation Sequencing TechnologyArtificial Intelligence/Machine Learning ApplicationsAI in Healthcare Adoption DriversLiquid Biopsy in Clinical DiagnosticsLiquid Biopsy Clinical ApplicationsLong-Read Sequencing TechnologyReal-World Data / Real-World EvidenceThe FDA Is Attempting to Define RWD and RWEAn Uptick of RWD and RWE PublicationsThe Benefits of Real-World EvidenceThe Challenges of Using RWD and RWEAn Active Playing Field of Commercial RWD PlayersClinical Genomics Adoption Challenges 9. COVID-19, THE HEALTHCARE DISRUPTER Diagnostics - Commercial Companies RevampingDiagnostics Companies Quickly PivotedCOVID-19, a Disrupter, but also an OpportunityViral Sequencing Reveals How SARSCo-V-2 Evolves and SpreadsCOVID-19 Resulted in Unprecedented Data SharingCOVID-19 and the Massive Disruptions to Clinical Trials Processes 10. COMMERCIAL CLINICAL SOLUTIONS / PRODUCT PROVIDERS Company ProfilesBC PlatformsBluebee (an Illumina company)ColorCongenicaDNAnexusFabric GenomicsFoundation MedicineFreenomeGenooxGenuity ScienceGoogle Life SciencesGRAILHelixIlluminaInvitaePierianDxQIAGENSeven BridgesSOPHiA GeneticsTempus 11. THE FUNDING SITUATION 12. APPENDIX Clinical Genomics End User TypesThe Computational Scientist/BioinformaticianThe Data ScientistThe Non-Computational CollaboratorThe Genetic CounselorThe Clinical GeneticistThe PhysicianThe Patient 13. ABBREVIATIONSFor more information about this report visit https://www.researchandmarkets.com/r/hfqr98 CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager firstname.lastname@example.org For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Three prominent members of the global Scrabble players’ organisation quit in response to the changes
Former Busted musician was briefly involved with the Church following a 2008 rehab stint
Starting from just £5, is the budget-friendly range a hit or miss?
(Bloomberg) -- Credit Suisse Group AG unloaded about $2 billion of stocks tied to the Archegos Capital Management blowup in the second such block sale since the bank wrote down the bulk of its exposure in the first quarter.The stock offerings included Discovery Inc. and Iqiyi Inc., adding to some $2.3 billion worth of shares tied to the debacle that the bank sold last week, according to people familiar with the matter. The trades follow a torrent of similar transactions that had already erased about $194 billion in market value as banks from New York to Zurich and Tokyo unwound leveraged equity bets by Bill Hwang’s family office.Shares of Credit Suisse fell as the sale adds to evidence that the Archegos collapse could impact the bank beyond the first quarter, when it took a 4.4 billion franc ($4.8 billion) writedown, its worst trading hit in more than a decade. While the Swiss bank has substantially reduced its exposure, transactions since the end of March weren’t included in the first-quarter results, a person familiar with the matter has said.Credit Suisse fell as much as 2.2% in early Zurich trading and was 1.2% lower by 9:43 a.m. The stock has lost 15% this year, compared with double-digit gains for an index that includes its European peers.A spokesperson for Credit Suisse declined to comment on the sale and whether the bank plans more such transactions.Hwang’s private investment firm became the center of one of the biggest margin calls of all time late last month, and represented one of the most spectacular failures of risk-management and oversight in recent memory. The downfall of Archegos will result in $10 billion of losses to banks, according to analysts at JPMorgan Chase & Co. The debacle could attract regulatory scrutiny and potential fines for the banks involved, the analysts said this week.Read more: Archegos Ripples Through Banks’ Lucrative Hedge Fund BusinessTuesday’s block trades -- which sold at the lower end of ranges -- included 19 million Class A shares of Discovery sold at $38.40, said one of the people, asking not to be identified discussing a private matter. In addition, 22 million Class C shares of Discovery sold at $32.35 while a stake of 35 million Iqiyi shares went for $15.85.Credit Suisse’s latest sale comes weeks after several rivals dumped their shares to skirt losses. While the firm was one of several global investment banks to facilitate the leveraged bets of Archegos, it was slower than others to unwind the positions and had initially tried to reach some sort of standstill agreement, people familiar with the matter have said.The strategy failed as rivals rushed to cut their losses. Global banks including Goldman Sachs Group Inc. and Deutsche Bank AG have told investors that they shed their Archegos-linked positions with little financial impact.Credit Suisse is now planning a sweeping overhaul of its hedge fund business. It has already announced plans to cut its dividend, suspend share buybacks and scrap bonuses for top executives.(Updates with Credit Suisse shares from third paragraph.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
Revenue Prospects by Type (Primary Packaging (Blisters, Bottles, Pouches, Tubes, Others), Secondary Packaging (Labelling for Parenteral and Injectable, Just in Time Labelling, Tyvek Blistering for Parenteral, Cartons, Others)), End Users (Drug Manufacturing Companies, Research Labs and CROs), Profiles of Leading Companies and Regional and Leading National Market Analysis.New York, April 14, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Clinical Trial Packaging and Labelling Market Forecast 2020-2030" - https://www.reportlinker.com/p06058481/?utm_source=GNW Clinical Trial Packaging and Labelling- our new study reveals trends, R&D progress, and predicted revenues Where is the Clinical Trial Packaging and Labelling market heading? If you are involved in this sector you must read this newly updated report. This report shows you the potential revenues streams to 2030, assessing data, trends, opportunities and business prospects there. Discover how to stay ahead Our 171 pages report provides 96 tables, 50 charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Clinical Trial Packaging and Labelling Market. See how to exploit the opportunities. Forecasts to 2030 and other analyses reveal the commercial prospects • In addition to revenue forecasting to 2030, our new study provides you with recent results, growth rates, and market shares. • You find original analyses, with business outlooks and developments. • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments. Discover sales predictions for the world market and submarkets Along with revenue prediction for the overall world market, there are following segments, each forecasted at a global and regional level. Clinical Trial Packaging and Labelling Market by Type Primary Packaging • Blisters • Bottles • Pouches • Tubes • Others Secondary Packaging • Labelling for Parenteral and Injectable • Just in Time Labelling • Tyvek Blistering for Parenteral • Cartons • Others Clinical Trial Packaging and Labelling Market by End Users • CRO’s • Drug Manufacturing Companies • Research Labs In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 17 leading national markets: North America • U.S. • Canada • Latin America: • Brazil • Mexico • Rest of Latin America Europe (EU) • Germany • France • UK • Italy • Spain • Rest of Europe Asia-Pacific (APAC) • Japan • China • India • Australia • ASEAN • Rest of Asia-Pacific Middle East and Africa (MEA) • GCC Countries • South Africa • Rest of MEA Leading companies and the potential for market growth Overall world revenue for Clinical Trial Packaging and Labelling Market will surpass $900 million in 2020, our work calculates. We predict strong revenue growth through to 2030. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead. How the Clinical Trial Packaging and Labelling Market report helps you In summary, our 181 pages report provides you with the following knowledge: • Revenue forecasts to 2030 for 5 regional and 17 key national markets- See forecasts for the Clinical Trial Packaging and Labelling market in North America, Latin America, Europe, Asia-Pacific and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, Spain, China, India, Japan, Australia, ASEAN countries, GCC Countries and South Africa. • Prospects for established firms and those seeking to enter the market- including company profiles for 13 of the major companies involved in the Clinical Trial Packaging and Labelling market Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence. Information found nowhere else With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. This study is for everybody needing commercial analyses for the Clinical Trial Packaging and Labelling market and leading companies. You will find data, trends and predictions.Read the full report: https://www.reportlinker.com/p06058481/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: email@example.com US: (339)-368-6001 Intl: +1 339-368-6001
Readily known by her first name, Shirley Williams, once tipped to become the first female prime minister, enhanced the quality of public life
Envoy says global warming ‘must stand alone’ in great power relations, despite disagreements elsewhere
Dublin, April 14, 2021 (GLOBE NEWSWIRE) -- The "Asphalt Pavers Market Share, Size, Trends, Industry Analysis Report, By Product Type; By Screed Type; By Operating Weight; By Paving Width; By Regions; Segment Forecast, 2020-2027" report has been added to ResearchAndMarkets.com's offering. The global asphalt pavers market size is expected to reach USD 1,410.03 million by 2027China is focusing on the development of its western region. In line with this, it has announced various infrastructure projects for the Tibet region as well. India is mainly focusing on the development of its transport network by investing heavily in road and rail infrastructure. Furthermore, the country is focusing on improving power infrastructure by building thermal, nuclear, wind, and solar power stations.Traffic has grown by 150 times over the last 50 years, while roads have increased by 9 times during the same period. The quality of roads in India is quite poor, leading to annual economic losses of US$ 4 Bn to US$ 7 Bn. The Indian construction equipment market has the potential to grow up to significantly, owing to the government's focus on infrastructure developments.Intelligent pavement refers to the pavement of asphalt using asphalt pavers equipped with global positioning systems (GPS) based mapping sensors and optional feedback controls. It is one of the most important progress made in roadway construction and has been widely adopted by Europe and China's manufacturers.In order to meet the changing need of the European market coupled with increasing demand for higher levels of operator comfort and safety. Despite their smaller dimensions, manufacturers are continuing to improve the operator's working environment by adding more comfort and safety features to their machines. For instance, Hamm's newly launched Asphalt Pavers enhance maximum possible operators' comfort, exceptionally good visibility, and the highest possible operational safety.Market participants such as Caterpillar, Sunroc Corporation, Astec Industry, Gencor Industries, Inc., Wirtgen group, Volvo CE, Ammann, Sumitomo, Fayat Group, Sany, Zoomlion, VT Leeboy, Shantui, and XCMG are some of the key players operating in the global market. Market players are focusing on mergers, acquisitions, technological advancements to have a competitive edge in the market. For instance, in July 2020, Gencor Industries announced a definitive agreement to acquire paver business from Blaw Knox, the Pennsylvania, U.S. based paver equipment manufacturer. Key Topics Covered: 1. Introduction2. Executive Summary3. Research Methodology3.1. Overview3.2. Data Sources4. Asphalt Pavers Market Insights4.1. Asphalt Pavers - Industry snapshot4.2. Asphalt Pavers Market Dynamics4.2.1. Drivers and Opportunities22.214.171.124. Strong government funding126.96.36.199. Introduction of new technologies4.2.2. Restraints and Challenges188.8.131.52. Cost escalations4.3. Porter's Five Forces Analysis4.4. PESTLE Analysis4.4.1. Asphalt Pavers Market Industry trends5. Asphalt Pavers Market Assessment by Product Type5.1. Key Findings5.2. Introduction5.3. Tracked Pavers5.4. Wheeled Pavers6. Global Asphalt Pavers Market, by Screed Type6.1. Key Findings6.2. Introduction6.3. Hydrostatic6.4. Mechanical7. Global Asphalt Pavers Market, by Operating Weight7.1. Key Findings7.2. Introduction7.3. 5000-8000 Kgs7.4. 8000-12000 Kgs7.5. 12000-15000 Kgs7.6. Over 15000 Kgs8. Asphalt Pavers Market Assessment by Paving Width8.1. Key Findings8.2. Introduction8.3. Up to 1.5 m8.4. 1.5-2.5 m8.5. 2.5-5 m8.6. Over 5 m9. Asphalt Pavers Market Assessment by Geography9.1. Key findings9.2. Introduction9.2.1. Asphalt Pavers Market Assessment, By Geography, 2016-2027 (USD Million)10. Competitive Landscape10.1. Expansion and Acquisition Analysis10.1.1. Expansion10.1.2. Acquisitions10.2. Partnerships/Collaborations/Agreements/Exhibitions11. Company Profiles11.1. Company Overview11.2. Financial Performance11.3. Product Benchmarking11.4. Recent Developments CaterpillarAstec IndustryWirtgen groupVolvo CEAmmannSumitomoFayat GroupSanyZoomlionVT LeeboyShantuiXCMG For more information about this report visit https://www.researchandmarkets.com/r/nmqivk CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager firstname.lastname@example.org For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900